ARTICLE | Management Tracks
Peter Maag resigns as Kyverna CEO
Plus: Ginkgo CEO Jason Kelly steps down from federal biotech advisory group, and updates from Lexicon, Arsenal, Ray and more
September 17, 2024 1:03 AM UTC
With its share price flagging seven months after its IPO, Kyverna Therapeutics Inc. (NASDAQ:KYTX) said Peter Maag has resigned as its CEO and from its board, ending a two-year stint at the cell therapy company focused on autoimmune disease.
Warner Biddle, who was SVP and global head of commercial at the Kite Pharma cell therapy unit of Gilead Sciences Inc. (NASDAQ:GILD), will succeed him as CEO and take a board seat. Christi Shaw, a veteran pharma executive who was Kite’s CEO in 2019-23, is also joining Kyverna’s board...